Measuring effectiveness.

Measuring the effectiveness of medical interventions faces three epistemological challenges: the choice of good measuring instruments, the use of appropriate analytic measures, and the use of a reliable method of extrapolating measures from an experimental context to a more general context. In practice each of these challenges contributes to overestimating the effectiveness of medical interventions. These challenges suggest the need for corrective normative principles. The instruments employed in clinical research should measure patient-relevant and disease-specific parameters, and should not be sensitive to parameters that are only indirectly relevant. Effectiveness always should be measured and reported in absolute terms (using measures such as 'absolute risk reduction'), and only sometimes should effectiveness also be measured and reported in relative terms (using measures such as 'relative risk reduction')-employment of relative measures promotes an informal fallacy akin to the base-rate fallacy, which can be exploited to exaggerate claims of effectiveness. Finally, extrapolating from research settings to clinical settings should more rigorously take into account possible ways in which the intervention in question can fail to be effective in a target population.

[1]  Gordon H Guyatt,et al.  How to generalize efficacy results of randomized trials: recommendations based on a systematic review of possible approaches. , 2013, Journal of evaluation in clinical practice.

[2]  J. Fuller Rationality and the generalization of randomized controlled trial evidence. , 2013, Journal of evaluation in clinical practice.

[3]  Paul Teller The concept of measurement-precision , 2012, Synthese.

[4]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[5]  J. Kragstrup,et al.  Danish GPs' perception of disease risk and benefit of prevention. , 2002, Family practice.

[6]  J. Stegenga Effectiveness of medical interventions. , 2015, Studies in history and philosophy of biological and biomedical sciences.

[7]  Jesper Nielsen,et al.  Laypersons' understanding of relative risk reductions: Randomised cross-sectional study , 2008, BMC Medical Informatics Decis. Mak..

[8]  C D Naylor,et al.  Measured Enthusiasm: Does the Method of Reporting Trial Results Alter Perceptions of Therapeutic Effectiveness? , 1992, Annals of Internal Medicine.

[9]  J. Dupré Across the Boundaries: Extrapolation in Biology and Social Science , 2010 .

[10]  J. Swanson,et al.  The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. , 2009, Journal of the American Academy of Child and Adolescent Psychiatry.

[11]  Ines Fischer,et al.  Scientific Representation: Paradoxes of Perspective , 2009 .

[12]  B. Demichelis,et al.  Completeness of reporting trial results: effect on physicians' willingness to prescribe , 1994, The Lancet.

[13]  Eran Tal How Accurate Is the Standard Second? , 2011, Philosophy of Science.

[14]  Martin Schweitzer,et al.  Measuring the success of public participation on environmental restoration and waste management activities in the U.S. Department of Energy , 1998 .

[15]  Eric M. Meslin,et al.  The Ethics of Information: Absolute Risk Reduction and Patient Understanding of Screening , 2008, Journal of General Internal Medicine.

[16]  N. Hadler Overtreated: Why Too Much Medicine Is Making Us Sicker and Poorer , 2007 .

[17]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[18]  Leah McClimans The role of measurement in establishing evidence. , 2013, The Journal of medicine and philosophy.

[19]  D. Moher,et al.  How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[20]  Robert D Gibbons,et al.  3-year follow-up of the NIMH MTA study. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  Eran Tal,et al.  Making Time: A Study in the Epistemology of Measurement , 2016, The British Journal for the Philosophy of Science.

[22]  M. Susser,et al.  Philosophy in epidemiology , 1991, Theoretical medicine.

[23]  Jacob Stegenga,et al.  Is meta-analysis the platinum standard of evidence? , 2011, Studies in history and philosophy of biological and biomedical sciences.

[24]  J. Howick Exposing the Vanities—and a Qualified Defense—of Mechanistic Reasoning in Health Care Decision Making , 2011, Philosophy of Science.

[25]  M Egger,et al.  The causes and effects of socio-demographic exclusions from clinical trials. , 2005, Health technology assessment.

[26]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[27]  R M Arnold,et al.  Absolutely relative: how research results are summarized can affect treatment decisions. , 1992, The American journal of medicine.

[28]  Nancy Cartwright Evidence, external validity and explanatory relevance. , 2011 .

[29]  A. Alexandrova First-Person Reports and the Measurement of Happiness , 2008 .

[30]  R. Kuhn,et al.  International Studies in the Philosophy of Science , 2009 .

[31]  Michael G. Samarkos,et al.  The philosophy of Evidence-based Medicine , 2006 .

[32]  Jon Williamson,et al.  Interpreting Causality in the Health Sciences , 2007 .

[33]  P. Rothwell,et al.  External validity of randomised controlled trials: “To whom do the results of this trial apply?” , 2005, The Lancet.

[34]  Leah McClimans A theoretical framework for patient-reported outcome measures , 2010, Theoretical medicine and bioethics.

[35]  A. Waldman,et al.  Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials , 2014, Multiple sclerosis international.

[36]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.

[37]  D. Eyding,et al.  Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials , 2010, BMJ : British Medical Journal.

[38]  J. Worrall Do We Need Some Large, Simple Randomized Trials in Medicine? , 2010 .

[39]  Phyllis Illari,et al.  Mechanistic Evidence: Disambiguating the Russo–Williamson Thesis , 2011 .

[40]  Jacob Stegenga,et al.  Probabilizing the end , 2013 .